Introduction
BMT remains one of the only curative options available to treat progressive anaemia, combined immunodeficiency and/or lymphoma development in the context of DNA damage response-defective disorders, such as Fanconi anaemia and Nijmegen breakage syndrome. 1, 2 Nonmyelo-ablative haematopoietic stem cell transplantation (NHSCT) using reduced doses of DNA damaging agents has improved the success rate for transplantation in this context. 1, 3 Several human disorders have now been described that are defective in non-homologous end-joining (NHEJ), the principal pathway by which human cells repair DNA double-strand breaks (DSBs). 4, 5 These include DNA ligase IV syndrome (LIG4), which is caused by hypomorphic mutations in DNA ligase IV, Artemis-dependent SCID (ART-SCID), caused by mutations in the Artemis endonuclease and XRCC4-like factor (XLF)/Cernunnosdependent SCID, caused by mutations in an XLF/ Cernunnos. [5] [6] [7] [8] Increased cellular and clinical radiosensitivity is a feature of these conditions due to their failure to repair ionizing radiation-induced DSBs. 6 Because of the central role played by NHEJ in V(D)J recombination all of these disorders initially present with moderate-to-severe combined immunodeficiency necessitating clinical intervention often culminating in BMT. 9 But, anecdotal (unpublished data) and evidence from other studies suggest that LIG4 syndrome patients are particularly poorly following BMT (Table 1) . Indeed, there is only one detailed report of a successful BMT in LIG4 syndrome using NHSCT with a modified conditioning regimen. 12 This is in marked contrast to that of ART-SCID where NHSCT has been used successfully in these patients even before the underlying causative genetic defect was identified. 9, 13, 14 The reason for the difference in response in these two patient groups that display similar levels of radiosensitivity is unclear. To date, there has not been a report of BMT in XLF/Cernunnosdependent SCID.
The agents commonly employed as part of the conditioning regimen prior to NHSCT include BU (Myerlan), a bi-functional DNA crosslinking agent, fludarabine (FluD) (Fludara), a nucleoside analogue and MTX (Amethopterin), a dihydrofolate reductase inhibitor. All of these compounds can induce DSBs either directly or indirectly. CsA is a widely used prophylaxis for GVHD, which represents a significant post transplantation complication. 15, 16 CsA binds to the cyclophilin class of proteins that can then function as an inhibitor of calcineurin, a serine-threonine phosphatase (also called PP2B). CsA's utility as an immunosuppressive agent is thought to derive from its ability to prevent nuclear localization of transcription factor NFAT (nuclear transcription factor in activated T cells). 17 NFAT is involved in the transcription of various cytokines (for example IL-2) that are required to activate T cells. Inhibition of NFAT nuclear localization by CsA results in profound systemic immunosuppression. Because of the poor clinical outcome of LIG4 syndrome patients to BMT we set out to investigate whether the failure to repair DSBs induced by the agents used during NHSCT could have a disproportionately adverse impact in the context of LigIV À/À deficiency. Using the methylthiazolyldiphenyl-tetrazolium bromide (MTT) assay, we evaluated the sensitivity of human pre-B lymphocytes either proficient or engineered by gene targeting to be deficient for LigIV À/À to the components employed clinically as part of the conditioning regimen prior to BMT and for GVHD prophylaxis. These included BU, FluD, MTX and CsA. Furthermore, using an indirect immunofluorescence assay based on 53BP1 foci formation as a sensitive marker for DSBs, we evaluated the impact of BMT conditioning regimens on DSB formation and repair in NHEJ-defective human cells.
Materials and methods

Cell lines
Wild-type (WT; Nalm 6) and LigIV À/À (N114-P2) pre-B human lymphocyte cells have been described previously. 18 These cells were cultured in RPMI-1640 supplemented with L-glutamine and 15% FCS. Primary human skin fibroblasts were grown in MEM supplemented with L-glutamine and 15% FCS. The WT (1BR.3), LIG4 syndrome (LIG4; 411BR) and Artemis-SCID (ART-SCID; CJ179) have been described elsewhere. 6, 19 The LIG4 syndrome fibroblast was derived from a 9-year-old patient with three homozygous alterations in LigIV À/À (8C4T(A3V), 26C4T(T9I) and 833G4A(R278H)). 6 The ART-SCID fibroblast (CJ179) was derived from an immuno-deficient child and fails to express a detectable Artemis transcript due to a genomic deletion. 19 
Drugs
All drugs/chemicals were obtained from Sigma-Aldrich UK Ltd (Poole, UK) and made up fresh prior to each survival. BU was dissolved in DMSO and made up to 5 mM in PBS (p2% v/v DMSO). FluD and CsA were dissolved in DMSO. Methyl methane sulphonate (MMS) was diluted in complete medium.
Antibodies
Anti-53BP1 (BL181) antibody was obtained from Universal Biologicals (Cambridge, UK). Anti-bromodeoxyuridine (BrdU; Bu20A) antibody was obtained from Autogen BioClear (Wiltshire, UK).
Immunofluorescence-based DNA DSB repair assay Immunofluorescence-based detection of 53BP1 foci formation using an anti-53BP1-specific antibody was used as an indirect highly sensitive assay for monitoring DNA DSB formation and repair, as previously characterized.
19 53BP1 is one of many proteins recruited to a DSB. Following treatment of primary fibroblasts with various agents, single DSBs are visualized indirectly as discrete microscopically detectable 53BP1 foci. Cells were also treated with 50 mM This patient died of possible VOD following treatment with BU (50 mg per day) and cyclophosphamide (500 mg per day)
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This patient was diagnosed as LIG4 prior to transplantation hence a NHSCT protocol was applied. BrdU to label S-phase cells that were specifically visualized following immunofluorescence using an anti-BrdU antibody. Standard immunofluorescence procedures for primary skin fibroblast have been described in detail elsewhere. 19 Images were captured using a Zeiss-Axioplan microscope using Simple-PCI software.
MTT assay
For MTT survival analysis cells were treated in RPMI-1640 without phenol red (Fischer Scientific UK Ltd, Loughborough, Leicestershire, UK) in 24-well plates and grown for 5 days. The drug(s) was not removed. MTT dissolved in RPMI-1640 without phenol red was added to each well (0.5 mg/ml) and incubated for 3-6 h to allow the insoluble formazan crystals to form. Acidic iso-propanol (40 mM HCl in absolute iso-propanol) was added to each well to dissolve the formazan crystals. Following removal of cell debris by centrifugation, absorbance of the converted dye was measured at 570 nm with background subtraction at 650 nm.
Results
We specifically chose human pre-B lymphocytes for analysis as these represent an important target population for conditioning regimens. We treated WT and Lig IV À/À human pre-B lymphocytes with BU, FluD and MTX either alone (Figure 1a -c) or in various combinations (Figure 1d ) and determined survival after 5 days using MTT analysis. We failed to find any significant sensitivity in the absence of Lig IV À/À to any of these agents individually (Figure 1a-c) . Furthermore, no additional significant sensitivity was observed in LigIV À/À pre-B lymphocytes when they were treated with all of these agents simultaneously (Figure 1d ). This data suggest that complete loss of LigIV À/À does not selectively significantly sensitize human pre-B lymphocytes to BU, FluD or MTX. Furthermore, when used in combination, these compounds do not act to synergistically sensitize human pre-B lymphocytes deficient for LigIV
CsA is currently a cornerstone for the treatment and/or prevention of GVHD. 16 Unexpectedly, we found that Lig IV À/À human pre-B lymphocytes were selectively sensitive to killing by CsA (Figure 2a) . Similarly, when CsA was used in combination with BU and FluD, we found that the LigIV À/À pre-B lymphocytes were more sensitive than their WT counterparts (Figure 2b ). Since LigIV À/À functions as a core component in one of the principal DNA DSB repair pathways, NHEJ, we investigated the possibility that this selective sensitivity of LigIV À/À cells towards CsA could be the consequence of CsA-induced DSB formation. It has not been previously reported that CsA can, either directly or indirectly, induce DSBs. Following DSB formation in mammalian cells, one of the earliest detectable responses is the phosphorylation (ATM and DNA-protein kinase dependent) of the histone H2A variant H2AX (termed g-H2AX). It has been shown that DSB formation and repair can be very sensitively monitored in cells by indirect immunofluorescence microscopy using antibodies specific for g-H2AX.
19 It has been shown that each discrete microscopically detectable g-H2AX focus likely represents a single DSB. [20] [21] [22] To monitor DSB formation we used primary skin fibroblasts that are more amenable to this type of microscopic analysis compared to lymphocytes. 53BP1 is one of many proteins recruited very rapidly to a DSB. Microscopically detectable 53BP1 foci are formed, co-localize and are repaired with the same kinetics as those of g-H2AX.
19,23 For practical reasons (to allow co-staining with anti-BrdU) we utilized 53BP1 foci formation as a surrogate marker for DSBs instead of monitoring g-H2AX foci formation (Figure 3a) . We used exponentially growing primary fibroblasts from a clinically unaffected (WT), a radiosensitive DSB repair-defective LIG4 patient and Artemis-defective SCID patient (ART-SCID) that we previously characterized. 6, 19 Interestingly, we found an increased amount of DSBs (53BP1 foci) in cells that had traversed S-phase (BrdU positive ( þ ive)) following a 24 h treatment with CsA specifically in the LIG4 syndrome cells compared to WT and ART-SCID (Figure 3a and b) . 53BP1 foci were not observed in cells that did not stain for BrdU, under these conditions. Staining for S-phase cells using anti-BrdU showed that all of the cell lines had comparable levels of S-phase cells (20-23%) and were therefore growing at similar rates. This indicates that CsA treatment results in DSB formation in cells that have traversed S-phase and that these breaks persist in LIG4 syndrome cells specifically.
A likely mechanism for DSB formation during S phase is the collision of replication forks with single-stranded DNA breaks (SSBs). SSBs occur spontaneously at high levels in mammalian cells but are usually repaired rapidly by the base excision repair pathway (BER). [24] [25] [26] [27] CsA has been proposed to inhibit DNA damage-induced overexpression of DNA polymerase b, which plays an important role in BER. 26, 28 To examine whether CsA might enhance the persistence or formation of DSBs following replication, we examined the impact of CsA on DSBs arising following treatment with MMS, an agent that can induce SSBs in S-phase (Figure 3c ). Following exposure to 1 mM MMS for 1 h and incubation for a further 24 h, a small increase in DSBs (5-8 53BP1 foci) was observed in WT, LIG4 syndrome and ART-SCID primary fibroblasts that had traversed S-phase (BrdU þ ive). Non-BrdU-labelled cells showed no increase in DSB formation suggesting that DSB formation is replication dependent. This is consistent with the notion that DSBs can arise following replication of SSBs but that under normal conditions they are rapidly repaired. Strikingly, when CsA (5 mM) was included with MMS, a significant increase in DSBs was observed, specifically in LIG4 syndrome fibroblasts (23) (24) (25) (26) (27) (28) (29) (30) foci) compared to WT or ART-SCID (5-10 53BP1 foci). This suggests that CsA-induced DSBs can form, likely indirectly, from SSBs during S-phase. Furthermore, these DSBs specifically persist in LIG4 syndrome cells compared to ART-SCID (Figure 3c) .
Finally, we examined whether the increased sensitivity of LigIV À/À cells to combined treatment with CsA, BU and FluD, conditions which mimic NHSCT conditioning and GVHD prophylaxis, was a consequence of increased DSB formation (Figure 4) . Using WT and LIG4 syndrome primary fibroblasts, following treatment with modest concentrations of BU (5 mM) together with FluD (1 mM), no significant difference in DSBs was observed between these cell lines (Figure 4 ; BU þ FluD). This was distinct to treatment with CsA (5 mM) alone where an increased level of DSBs were observed in LIG4 syndrome cells derived from S-phase specifically ( Figure 4 CsA and Figure 3b ). Strikingly, when these cell lines were treated for 24 h with CsA (5 mM) simultaneously with BU (5 mM) and FluD (1 mM), a significant increased level of DSBs were now observed specifically in the LIG4 syndrome cells compared to WT (Figure 4 ; BU þ FluD þ CsA). This data suggest that CsA can induce DSBs alone but particularly in combination with BU and FluD and that these DSBs remain at an elevated level in LIG4 syndrome-derived patient cells.
Collectively our data identify CsA as an important source of DSBs especially when used in combination with BU and FluD, similarly to conditions used for NHSCT conditioning and GVHD prophylaxis. Furthermore, À/À human pre-B lymphocytes were treated simultaneously with BU (5 mM), FluD (1 mM) and CsA (2 mM) and survival determined after 5 days culture using the MTT assay. Drugs were not removed.
LigIV
À/À pre-B lymphocytes and LIG4 syndrome primary fibroblasts are particularly sensitive to CsA-induced DSB formation.
Discussion
NHSCT using reduced doses of DNA damaging agents has significantly improved the outcome of BMT in individuals compromised for DNA repair. 1, 14 But, LIG4 syndrome patients, particularly compared to ART-SCID, generally have a poorer outcome. 5, [9] [10] [11] 13, 14 Multiple factors could be responsible for this, especially the general health of the patients prior to conditioning. Nevertheless, since compounds that can form DSBs are used during NHSCT, we sought to determine whether LigIV À/À deficiency could adversely hypersensitize individuals to such treatments. Here, we report the first detailed evaluation of the response of LigIV À/À -defective cells to the compounds used for BMT and GVHD prophylaxis. We found that human LigIV À/À pre-B lymphocytes are not significantly selectively sensitive to BU, FluD or MTX alone or when treated with these agents simultaneously. Unexpectedly, we found that LigIV À/À pre-B human lymphocytes were selectively sensitive to CsA, probably the most widely used prophylaxis for GVHD. Furthermore, when CsA was used in combination with BU and FluD, these cells exhibited significant hypersensitivity. Crucially, we found that CsA treatment resulted in DSB formation even in non-haematopoetic human cells (primary skin fibroblasts). We suggest that these DSBs arise likely indirectly from SSBs occurring during DNA replication. Importantly, we showed that these CsA-induced DSBs are formed at increased levels in LigIV À/À -deficient background following co-treatment with BU and FluD. Finally we showed that these DSBs are repaired with slower kinetics in the absence of LigIV À/À compared to Artemis deficiency.
Our data unexpectedly identified CsA as an agent capable of causing DSB formation in human cells specifically following replication. Interestingly, CsA treatment, either alone or in combination with other BMT drugs, did not result in an increased level of DSBs in ART-SCID fibroblasts compared to those of LIG4 syndrome. The roles of Artemis and LigIV À/À in NHEJ are distinct. 19, 29 LIG4 syndrome cells show slow kinetics of repair of all DSBs, while ART-SCID cells rejoin the majority of DSBs with normal kinetics but are defective in a specific subset of DSBs. Increased levels of residual CsAinduced DSBs seen in the LIG4 syndrome cells are likely a result of their general inability to repair all types of DSBs compared to ART-SCID cells. This provides a provocative potential explanation as to why ART-SCID individuals routinely successfully undergo NHSCT compared to LIG4 syndrome. Our findings also add weight to the increasing evidence that NHEJ can function to repair replicationassociated DSBs, which has previously been proposed to be carried out by homologous recombination. 30 CsA is used as prophylaxis for GVHD, but GVHD treatment protocols vary significantly. 16 A previous study among the European Group for Blood and Marrow Transplantation (EBMT) found that CsA treatment protocols and target doses vary widely among European transplantation centres. 31 While the average initial daily dose of CsA was 3 mg/kg (i.v.) the range was 1-20 mg/kg (i.v.). Target CsA blood concentrations ranged from 250 to 400 mg/l, which is equivalent to 0.19-0.3 mM CsA. While these low mM concentrations represent an approximately 10-fold difference to those used in our experiments (2-5 mM), crucially, our cellular work utilized a short-term exposure to a single dose of CsA. The cumulative effect on DSB formation from repeated or chronic exposure to low mM concentrations of CsA could be physiologically relevant. Interestingly, the LIG4 syndrome patient that successfully underwent NHSCT recently reported by Gruhn et al., 12 received a CsA dosage at the lower end of the European range (3 mg/kg per day). 31 Our data suggest that caution should be exercised regarding CsA treatment regimens specifically in the context of LIG4 syndrome.
An important general implication of our findings that CsA can form DSBs relates to malignancy. Long-term use of calcineurin inhibitors such as CsA in solid organ and BMT is associated with increased risk of cancer. [32] [33] [34] While immunosuppression appears to be the principal predisposing factor, others have argued that compounds such as CsA can also inhibit the repair of DNA damage. 33, [35] [36] [37] A precedent for the role of immunosuppressive agent-induced DNA damage likely impacting on cancer predisposition has recently been described regarding azathioprine. 38, 39 Unrepaired DSBs can result in deletions and/or act as a platform for translocations with obvious implications for malignant transformation. [40] [41] [42] If prolonged CsA treatment induces persistent DSBs this could compromise genomic stability not just in the context of LigIV À/À deficiency. Whether this could play any role in BMT-derived secondary cancers is unclear, although worthy of further investigation. 32, 43 
